Common Equity: The sum of all common equity items.
Regencell Bioscience Holdings Limited (RGC) had Common Equity of $13.35M for the most recently reported fiscal year, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-11.70M |
|
-- |
|
-- |
|
$11.72M |
|
$-11.72M |
|
$0.02M |
|
$-11.70M |
|
$-11.70M |
|
$-11.70M |
|
$-11.70M |
|
$-11.70M |
|
$-11.70M |
|
$-11.72M |
|
$-11.64M |
|
494.60M |
|
494.60M |
|
$-0.02 |
|
$-0.02 |
|
| Balance Sheet Financials | |
$14.22M |
|
$0.14M |
|
$0.51M |
|
$14.73M |
|
$1.32M |
|
-- |
|
$0.06M |
|
$1.38M |
|
|
Common Equity |
$13.35M |
$13.35M |
|
$13.35M |
|
495.88M |
|
| Cash Flow Statement Financials | |
$-7.70M |
|
$2.50M |
|
$16.95M |
|
$2.42M |
|
$14.19M |
|
$11.77M |
|
$3.23M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
10.77 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-7.70M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-87.66% |
|
-87.66% |
|
-79.45% |
|
-87.66% |
|
$0.03 |
|
$-0.02 |
|
$-0.02 |
|